To assess target downregulation and efficacy in vivo, murine-specific CD39 ASOs (Additional file 3: Table S2) were tested in vitro in mouse cancer cell line A20 (B cell lymphoma) from which the most potent mCD39-specific ASO A04011MR was selected as candidate (Additional file 4: Figure S2) for in vivo experiments. This evidence concerns the gene ENTPD1 and B-cell non-Hodgkin lymphoma.